Syndicate content

Aethlon Announces Cancer Clinical Trial Agreement with UC Irvine to Assess Plasma Exosome Concentration in Cancer Patients Undergoing Treatment; Company Has Candidate Device to Reduce Presence of Circulating Tumor-Derived Exosomes

In an April 15, 2015 press release, Aethlon Medical, Inc. (OTCQB:AEMD) (http://www.aethlonmedical.com/), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that it has entered into an investigator-initiated clinical trial agreement with the University of California, Irvine (UCI). Under the agreement, a clinical study protocol entitled, "Plasma Exosome Concentration in Cancer Patients Undergoing Treatment," will seek to enroll five individuals in each of nine defined tumor types for a total study population of up to 45 subjects. The tumor types include the following forms of cancer; breast adenocarcinoma, colorectal, gastric & gastroesophageal, pancreatic, cholangiocarcinoma, lung (NSCLC), head & neck (SCC), melanoma, and ovarian adenocarcinoma. The principal investigator of the study is Edward Nelson, M.D. The study endpoints include establishing baseline exosome levels and monitoring changes in circulating exosome concentration associated with tumor treatment and the association of longitudinal changes in circulating exosome concentrations with response to treatment. The clinical study will also provide data to help direct future clinical investigations of the Aethlon Hemopurifier® as a therapeutic candidate to reduce the presence of circulating tumor-derived exosomes, which are known to suppress the immune system of cancer patients and contribute to the spread of metastasis. Aethlon Medical believes that the Hemopurifier is a first-in-class bio-filtration device that targets the single-use removal of viruses and tumor-derived exosomes from the circulatory system. Recruitment of participants in the study will be through the use of internal and outside referrals to the University of California, Irvine Medical Center (UCIMC). Review and approval of this human protocol will be conducted by the UCI Institutional Review Board (IRB) Human Subjects Review Committee. Aethlon Medical creates medical devices that target unmet therapeutic needs in infectious disease and cancer. The company's lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc (http://www.exosomesciences.com/) is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders

[Press release]